Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
NCT ID: NCT02137863
Last Updated: 2014-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2011-06-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Dexmedetomidine on Kidney Function in EVAR
NCT04766047
Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis
NCT02691598
The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity
NCT00632892
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
NCT00223548
Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
NCT02808351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.
1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography.
0.9 % NaCl
During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
0.9 % NaCl
100 ml/10min infusion just before the angiography
1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Dexmedetomidine
Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.
1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography.
Dexmedetomidine
Intravenously 1μg/kg/10min administered just before the procedure.
1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
0.9 % NaCl
During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Intravenously 1μg/kg/10min administered just before the procedure.
1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
0.9 % NaCl
During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
0.9 % NaCl
100 ml/10min infusion just before the angiography
1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \> 18 yo
* Diabetic patients
* Creatinin value \< 3 mg/dl
Exclusion Criteria
* Pregnant patients
* Creatinin value ≥3mg/dl
* patients have acute renal failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TC Erciyes University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aynur Akın
Prof Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aynur Akın, Prof
Role: STUDY_CHAIR
TC Erciyes University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011/345
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.